Overview

Solid tumor next-generation sequencing (NGS) has changed how clinicians approach advanced cancer by moving from a single-biomarker mindset to a broader molecular survey. A 106-gene solid tumor panel is designed to examine a curated set of genes that are frequently altered in cancer and that carry established or emerging links to therapy. Rather than testing one marker at a time, the assay reads millions of DNA fragments in parallel, producing a consolidated report that can surface mutations, gene fusions, copy-number changes, and signals such as microsatellite instability or tumor mutational burden. For buyers and partners in oncology distribution, understanding the underlying mechanism explains why such a panel is positioned as a medication-guidance tool rather than a standalone diagnostic verdict.

How the Sequencing Platform Works

NGS relies on massively parallel sequencing. After DNA is extracted from a tumor specimen—typically formalin-fixed paraffin-embedded tissue, fresh frozen tissue, or in some cases circulating tumor DNA from plasma—the relevant regions are captured and prepared into a library of fragments. Millions of these fragments are sequenced simultaneously. Bioinformatic pipelines then align the reads to a reference genome and call variants. The power of the method is breadth: a single run can interrogate hundreds of clinically relevant loci, which is far more efficient than running many separate polymerase-chain-reaction or immunohistochemistry tests.

What the 106 Genes Represent

The gene set on a focused solid tumor panel usually centers on oncogenes, tumor-suppressor genes, and DNA-repair pathways. Detecting an activating mutation in an oncogene may point toward a matched targeted agent, while loss of a tumor-suppressor gene or a homologous-recombination gene may inform other therapeutic strategies. The panel is intentionally narrower than a whole-exome scan, which keeps the report interpretable and turnaround manageable while still covering the alterations most often tied to approved or investigational therapies.

Turning Data into Medication Guidance

The output of a 106-gene panel is a variant list with interpretations ranked by clinical relevance. This supports discussions about targeted drugs, eligibility for clinical trials, and in some cases resistance mechanisms. It is important to recognize that sequencing results are one input among many; treatment decisions should be made by qualified clinicians using the full clinical picture, pathology, and local guidelines. The value of the test lies in consolidating complex genomic information into a single, actionable document.

FAQ

Q: What type of sample is needed for a solid tumor NGS panel? A: Most panels accept formalin-fixed paraffin-embedded tissue, and many also accept fresh frozen tissue or plasma-derived circulating tumor DNA, depending on the laboratory's validated workflow.

Q: Does a 106-gene panel replace broader genomic tests? A: No. It is a focused, clinically curated survey. Whole-exome or whole-genome approaches cover more of the genome but generate larger, less immediately actionable datasets.

Q: How should the results be used? A: Results should be interpreted by a qualified professional alongside pathology and guidelines to guide therapy or trial enrollment; they are decision-support information, not a prescription.